Implementation barriers and considerations for recommending and administering the human papillomavirus (HPV) vaccination in oncology settings.
AYA cancer survivors
HPV vaccine
Implementation science
Pediatric cancer survivors
Journal
Journal of cancer survivorship : research and practice
ISSN: 1932-2267
Titre abrégé: J Cancer Surviv
Pays: United States
ID NLM: 101307557
Informations de publication
Date de publication:
06 May 2023
06 May 2023
Historique:
received:
26
08
2022
accepted:
25
04
2023
pmc-release:
06
11
2024
medline:
6
5
2023
pubmed:
6
5
2023
entrez:
5
5
2023
Statut:
aheadofprint
Résumé
Survivors of childhood and adolescent cancer experience low human papillomavirus (HPV) vaccination rates-a crucial form of cancer prevention. Oncology provider recommendations may increase young survivors HPV vaccine intent, but HPV vaccination is not typically provided in the oncology setting. Thus, we explored the implementation barriers of providing the HPV vaccine in oncology. We interviewed oncology providers in a variety of specialty areas about their perceptions of the HPV vaccine and to explore barriers to recommending and administering the vaccine in their clinics. Interviews were audio recorded, quality checked, and thematically analyzed. Emergent themes were then mapped onto the Capability, Opportunity, Motivation, and Behavior (COM-B) Model and the Theoretical Domains Framework. A total of N=24 oncology providers were interviewed. Most provided direct clinical care (87.5%) and most commonly specialized in pediatric oncology (20.8%), medical oncology (16.7%), bone marrow transplant (16.7%), and nurse coordination (16.7%). Two themes emerged within each COM-B domain. Capability: 1) educational barriers to HPV vaccination and 2) complicated post treatment HPV vaccination guidelines. 1) perceived importance of HPV vaccine and 2) concern about blurred scope of practice. 1) hospital administration and time concern barriers and 2) clinical workflow integration concerns. Implementing HPV vaccination in the oncology setting has the potential to increase HPV vaccination rates among young survivors. Multi-level barriers to providing the HPV vaccine in the oncology setting were identified by participants. Leveraging existing implementation strategies may be an effective way to mitigate provider identified barriers and increase vaccination rates.
Sections du résumé
BACKGROUND
BACKGROUND
Survivors of childhood and adolescent cancer experience low human papillomavirus (HPV) vaccination rates-a crucial form of cancer prevention. Oncology provider recommendations may increase young survivors HPV vaccine intent, but HPV vaccination is not typically provided in the oncology setting. Thus, we explored the implementation barriers of providing the HPV vaccine in oncology.
METHODS
METHODS
We interviewed oncology providers in a variety of specialty areas about their perceptions of the HPV vaccine and to explore barriers to recommending and administering the vaccine in their clinics. Interviews were audio recorded, quality checked, and thematically analyzed. Emergent themes were then mapped onto the Capability, Opportunity, Motivation, and Behavior (COM-B) Model and the Theoretical Domains Framework.
RESULTS
RESULTS
A total of N=24 oncology providers were interviewed. Most provided direct clinical care (87.5%) and most commonly specialized in pediatric oncology (20.8%), medical oncology (16.7%), bone marrow transplant (16.7%), and nurse coordination (16.7%). Two themes emerged within each COM-B domain. Capability: 1) educational barriers to HPV vaccination and 2) complicated post treatment HPV vaccination guidelines.
MOTIVATION
BACKGROUND
1) perceived importance of HPV vaccine and 2) concern about blurred scope of practice.
OPPORTUNITY
METHODS
1) hospital administration and time concern barriers and 2) clinical workflow integration concerns.
CONCLUSION
CONCLUSIONS
Implementing HPV vaccination in the oncology setting has the potential to increase HPV vaccination rates among young survivors. Multi-level barriers to providing the HPV vaccine in the oncology setting were identified by participants. Leveraging existing implementation strategies may be an effective way to mitigate provider identified barriers and increase vaccination rates.
Identifiants
pubmed: 37147553
doi: 10.1007/s11764-023-01391-4
pii: 10.1007/s11764-023-01391-4
pmc: PMC10629381
mid: NIHMS1938180
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : P30 CA042014
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA216174
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA116339
Pays : United States
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
J Clin Oncol. 2007 Oct 10;25(29):4616-21
pubmed: 17925557
J Adolesc Young Adult Oncol. 2018 Apr;7(2):204-209
pubmed: 29346008
Cancer. 2019 Nov 1;125(21):3810-3817
pubmed: 31291010
Hum Vaccin Immunother. 2019;15(7-8):1767-1775
pubmed: 31116634
Vaccine. 2016 Feb 24;34(9):1187-92
pubmed: 26812078
Implement Sci. 2018 Apr 19;13(1):57
pubmed: 29673374
J Clin Oncol. 2017 Nov 1;35(31):3582-3590
pubmed: 28837404
PLoS One. 2013 Aug 05;8(8):e70349
pubmed: 23940566
Implement Sci. 2017 Jun 21;12(1):77
pubmed: 28637486
Vaccine. 2015 Apr 8;33(15):1773-9
pubmed: 25731788
Vaccine. 2011 Nov 3;29(47):8634-41
pubmed: 21924315
Implement Sci. 2011 Apr 23;6:42
pubmed: 21513547
J Am Board Fam Med. 2022 Mar-Apr;35(2):329-340
pubmed: 35379720
Implement Sci. 2015 Feb 12;10:21
pubmed: 25889199
Am J Manag Care. 2017 Nov 1;23(11):e353-e359
pubmed: 29182355
J Cancer Educ. 2018 Dec;33(6):1323-1327
pubmed: 28707205
Cancer. 2022 Jan 15;128(2):373-382
pubmed: 34606625
J Cancer Educ. 2022 Oct;37(5):1519-1524
pubmed: 33740231
Implement Sci. 2017 Aug 29;12(1):108
pubmed: 28851459
J Cancer Surviv. 2020 Oct;14(5):757-767
pubmed: 32458248
J Clin Oncol. 2016 May 20;34(15):1803-12
pubmed: 27069078
Am J Public Health. 2013 Jan;103(1):164-9
pubmed: 22698055
Cancer. 2009 Dec 15;115(24):5627-36
pubmed: 19813272
J Cancer Surviv. 2016 Jun;10(3):449-56
pubmed: 26572902
Stud Health Technol Inform. 2012;172:33-42
pubmed: 22910499
J Am Board Fam Med. 2015 May-Jun;28(3):324-33
pubmed: 25957365